Quercetin - based rhodium(III) complex: Synthesis, characterization and diverse biological potentials

Self Cite

A new copper (II) complex containing the mono basic ligand (HL) azo naringenin was synthesized and structurally characterized by analytical, magnetic, and various spectroscopic techniques. An octahedron geometry was proposed for the assigned molecular formula [Cu(L)(CH3COO)(OH2)2]. Processing of powder X‐ray diffraction data for the copper (II) complex in question by the Expo 2014 computer program confirmed the proposed structure inferred from the spectroscopic studies. The DNA binding ability of the free ligand and its copper (II) complex was tested, and the results obtained demonstrated the stronger DNA binding ability of the copper (II) complex over the azo naringenin ligand. The antioxidant potency of copper (II) complex was investigated via the DPPH free radical‐scavenging assay. The present azo naringenin ligand and its copper (II) complex have shown diverse biological potentials including antitumor, antifungal, and antibacterial activities.

Section: Resultsmentioning

confidence: 91%

“…This alternative approach to the structural analysis of metallic complexes has proven acceptable in several recent literatures. [44][45][46][47] Figure 7 shows the graphical representation of the good fitting between the theoretical and practical data based on Rietveld Refinement.…”

Section: T a B L Ementioning

confidence: 99%

Azo naringenin‐based copper (II) complex as DNA binder: Synthesis, spectroscopic characterization, and diverse biological potentials

El‐Bindary,

Fathy

2024

Self Cite

“…After the MDA‐231 cells had been incubated with the IC 50 of complex ( 1 ) for 24 h, the cell cycle, apoptosis, and MMP9 levels were assessed using a flow cytometer as described in the previous study 27 and listed in the Supporting Information: Section 1.4.…”

Section: Methodsmentioning

confidence: 99%

Synthesis and characterization of novel Ru(III) complexes of 2‐aminopyrazine: Interaction with biomolecules, antineoplastic activity, and computational investigation

Aboelnga,

Sahyon,

Elsayed

2024

Self Cite

Ruthenium (III) complexes (1–3) of 2‐aminopyrazine (pyz) with general formula of [Hpyz][RuCl4(DMSO)(pyz)](1), Na[RuCl4(pyz)(DMSO)] (2), and (Hpyz)[RuCl4(pyz)2].2H2O (3) have been synthesized and characterized by elemental analyses, FTIR, 1H NMR, and UV–visible spectroscopy, along with the magnetic susceptibility and cyclic voltammetry measurements. The molecular structures of the complexes have also been optimized using density functional theory (DFT) calculation which demonstrates an octahedral geometry to be adopted by the Ru(III) ion. The UV–visible and fluorescence spectra were employed to study the interaction of the compounds with nucleic acid (ctDNA and tRNA) and bovine serum albumin (BSA). The data showed a higher tendency for the ligand and its complexes (1–3) to interact with biomolecules (1 > 2 > 3). All complexes showed potent in vitro anticancer activity against three human cancer cell lines and high safety against normal cell lines as complex (1) is the most active one, it was selected for the flow cytometric evaluation for cell death mode, cell cycle analysis, and matrix metalloproteinase‐9 (MMP9) expression in treated MDA‐231 cells. Proliferating cell nuclear antigen (PCNA) expression and VEGF concentration were evaluated in the treated cells and compared with the untreated ones. Our study proved that complex (1) arrests the cell cycle, inhibits DNA transcription, reduces both MMP9 (validated by our molecular docking investigation targeting MMP9 protein) and PCNA expressions, and induces apoptotic cell death, leading to cancer metastasis prevention.

Dioxime palladium (II) complex: Synthesis, characterization, and dual anticancer mechanisms of topoisomerase II inhibition and Bax/caspase 3

Al‐Harbi

2024

The quadridentate tetraaza ligand (H2L) containing dioxime function groups and its palladium (II) complex [PdL] were synthesized and structurally characterized by analytical and various spectroscopic techniques (MS‐ES, 1HNMR, FTIR, UV–Vis, and PXRD in addition to SEM and EDX analysis). Processing powder X‐ray diffraction data and DFT calculations coupled with spectroscopic measurements revealed slightly distorted square planar stereochemistry. The anticancer activity of the newly synthesized dioxime palladium (II) complex, [PdL], has been studied and the findings of this study emphasize that [PdL] complex potentially combats cancer by exhibiting diverse cytotoxic impacts. These effects include reduced cell mitosis, decreased metastasis of MDA‐MB‐231 cancer cells, inhibition of topoisomerase II, and induction of apoptotic cell death. In conclusion, the present palladium (II) complex could be a potential therapeutic drug in breast cancer because it can reduce topoisomerase II expression, which is essential in metastasis. This inhibition also reduces the expression of CDK1, which plays an important role in cell cycle regulation.